Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.54 USD | +7.54% |
|
+4.72% | -30.34% |
04/06 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
09/05 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.34% | 978M | |
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris Narrows Q4 Net Loss; Hires New CFO